The use of TLR3-activated CB-MSCs may have supported antimicrobial treatment, highlighting the potential antimicrobial, anti-inflammatory, and immunomodulatory properties of CB-MSCs.

This study aimed to assess MSC treatment safety and efficacy. Higher return-to-exercise rates were expected in the MSC groups at 18 weeks, but unexpectedly high rates in the HA group may have led to underpowering. A post hoc calculation suggests 30 horses per group would be needed to detect significant differences.

A study assessed the safety and efficacy of a single administration of 10 million cryopreserved allogeneic mesenchymal stromal cells (MSC) that were either activated (aMSC) or non-activated (naMSC) for the treatment of synovitis.

repeated intralesional treatment using thawed pooled allogeneic equine CB-MSC results in positive clinical outcomes